Clinical observation of bevacizumab combined with sintilimab assisted intervention in patients with primary small liver cancer after microwave ablation
贝伐珠单抗联合信迪利单抗辅助干预微波消融后原发性小肝癌患者的临床观察

摘要

目的 分析贝伐珠单抗联合信迪利单抗辅助治疗对微波消融术后原发性小肝癌患者疗效与安全性的影响。方法 纳入50例接受微波消融的原发性小肝癌患者，随机对照临床研究分两组各25例，对照组行单纯消融治疗，试验组术后加用联合方案辅助治疗，随访对比两组生存指标、实验室指标与安全性差异。结果 试验组无进展生存期、缓解持续时间更长，术后复发时间更晚，肿瘤标志物下降更显著，两组不良反应发生率无统计学差异。结论 该联合辅助方案可延缓小肝癌消融后复发，改善短期疗效，且安全性可控。

Abstract

Objective To analyze the effect and safety of bevacizumab combined with sintilimab adjuvant therapy on patients with primary small liver cancer after microwave ablation.
Methods Fifty patients with primary small liver cancer who underwent microwave ablation were included in a randomized controlled clinical study, with 25 patients in each group. The control group received simple ablation treatment, while the experimental group received adjuvant treatment with a combination regimen after surgery. The survival indicators, laboratory indicators, and safety differences between the two groups were compared during follow-up.
Results The experimental group had a longer progression free survival period, longer duration of remission, later postoperative recurrence time, more significant decrease in tumor markers, and no statistically significant difference in the incidence of adverse reactions between the two groups.
Conclusion   This combined adjuvant therapy can delay the recurrence of small liver cancer after ablation, improve short-term efficacy, and have controllable safety.